41457-31-2

Basic information

• Product Name: Oxirane, [(2,3-dimethylphenoxy)methyl]-
• Synonyms: 2,3-dimethyl-1-(2,3-epoxypropoxy)benzene;1-(2,3-dimethyl)-phenoxy-2,3-epoxypropane;1,2-epoxy-3-[2,3-dimethylphenoxy]propane;2-(2,3-dimethyl-phenoxymethyl)-oxirane;Oxirane,[(2,3-dimethylphenoxy)methyl];1-xylenoxypropane-2,3-oxide
• CAS NO: 41457-31-2
• Molecular Formula: C11H14O2
• Molecular Weight: 178.231
• Mol File: 41457-31-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Oxirane, [(2,3-dimethylphenoxy)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxirane, [(2,3-dimethylphenoxy)methyl]-(41457-31-2)
• EPA Substance Registry System: Oxirane, [(2,3-dimethylphenoxy)methyl]-(41457-31-2)

Safety Data

• Hazardous Substances Data: 41457-31-2(Hazardous Substances Data)

Upstream product

• 526-75-0 2,3-Dimethylphenol 
• 106-89-8 epichlorohydrin 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 5790-06-7 1-Chloro-3-(2,3-dimethyl-phenoxy)-propan-2-ol 

Downstream Products

• 64980-33-2 1-(2,3-Dimethylphenoxy)propan-2-ol 
• 64980-39-8 1-Isopropylthio-3-(2,3-dimethylphenoxy)propan-2-ol 
• 30187-90-7 1-(2,3-dimethylphenoxy)-3-((1,1-dimethylethyl)amino)-2-propanol 
• 100822-58-0 4-(2,3-Dichlorophenyl)-7-[3-(2,3-dimethylphenoxy)-2-hydroxypropyl]-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-1,7-naphthyridine-3-carboxylic acid methyl ester 
• 256372-73-3 (S)-1-(2',3'-dimethylphenoxy)-2,3-epoxypropane 
• 64980-36-5 1-Isopropylamino-4-(2,3-dimethylphenoxy)butan-3-ol 
• 111794-27-5 3-[3-(2,3-Dimethyl-phenoxy)-2-hydroxy-propylamino]-N-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-propionamide 
• 802287-59-8 1-(2,3-dimethyl-phenoxy)-3-methylamino-propan-2-ol 
• 64980-38-7 1-Isopropyloxy-3-(2,3-dimethylphenoxy)propan-2-ol 
• 111794-54-8 3-{Benzyl-[3-(2,3-dimethyl-phenoxy)-2-hydroxy-propyl]-amino}-N-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-propionamide 
• 91623-00-6 5-<3-(2,3-dimethylphenoxy)-2-hydroxypropyl>-6a,7,8,9-tetrahydropyrido<3,2-e>pyrrolo<1,2-a>pyrazin-6(5H)-one 
• 91623-00-6 5-<3-(2,3-dimethylphenoxy)-2-hydroxypropyl>-6a,7,8,9-tetrahydropyrido<3,2-e>pyrrolo<1,2-a>pyrazin-6(5H)-one 

Relevant articles and documents

NBS/DMSO-mediated synthesis of (2,3-dihydrobenzo[b] [1,4]oxathiin-3-yl)methanols from aryloxymethylthiiranes

(2,3-Dihydrobenzo[b][1,4]oxathiin-3-yl)methanols were synthesized via reactions of aryloxymethylthiiranes and N-bromosuccinimide (NBS) in DMSO under microwave irradiation. The reaction mechanism was proposed as an intramolecular aromatic electrophilic substitution of 1-bromo-2-(aryloxymethyl)thiiran-1-iums, generated from aryloxymethylthiiranes and NBS, and the subsequent DMSO nucleophilic ring opening reaction of thiiran-1-iums followed by the water displacement. The current method provides a direct and simple strategy in the efficient preparation of (2,3-dihydrobenzo[b][1,4]oxathiin-3-yl)methanols from readily available aryloxymethylthiiranes.

CATHEPSIN PROTEASES INHIBITORS

The invention provides compounds (I) and pharmaceutical compositions thereof, and more particularly, bicyclic carbamates, which are useful as cathepsin inhibitors, and methods for using such compounds or pharmaceutically acceptable salts thereof, wherein

Design and synthesis of a series of combined vasodilator/β-adrenoceptor antagonists based on 6-arylpyridazinones

A series of new 6-[4-[[(aryloxy)acyl]amino]phenyl]-4,5-dihydropyridazinones have been synthesized and evaluated as combined vasodilator/β-adrenoceptor antagonists and potential antihypertensive agents. Many of the early compounds displayed an unacceptably high level of intrinsic sympathomimetic activity (ISA) and a relatively short duration of action. Disubstitution in the 2,3-positions or in the 4-position of the aryloxy ring gave compounds with low ISA levels and, in some instances, improved duration of action. All of the compounds were vasodilators, but the 5-methylpyridazinone derivatives showed consistently greater antihypertensive activity than their 5-H lower homologues. Further detailed pharmacological investigations led to the selection of 6-[4-[3-[[2-hydroxy-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propyl]amino ]propionamido]phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone (4t) (SK&F 95018) as a development candidate.